Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update
November 08, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted...
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer
November 02, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted...
Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies
October 25, 2021 09:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted...
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer
September 22, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021 16:01 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia
August 18, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131
August 16, 2021 08:30 ET
|
Cellectar Biosciences
Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131) Agreement adds second manufacturer and expands Cellectar’s current supply capabilities FLORHAM PARK,...
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
August 09, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
July 13, 2021 09:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)
July 12, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...